Cost effectiveness of pharmacotherapy for the prevention of migraine: A markov model application

CNS Drugs

Volumn 24, Issue 8, 2010, Pages 695-712

  Yu, Junhua ^a   Smith, Kenneth J ^b   Brixner, Diana I ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Amitriptyline, therapeutic use; Antimigraines, therapeutic use; Cost effectiveness; Markov model; Migraine; Pharmacoeconomics; Propranolol, therapeutic use; Quality adjusted life years; Timolol, therapeutic use; Topiramate, therapeutic use; Valproate semisodium, therapeutic use

Indexed keywords

AMITRIPTYLINE; PROPRANOLOL; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANOREXIA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FATIGUE; HEALTH STATUS; HUMAN; HYPESTHESIA; MEDICAL SOCIETY; MIGRAINE; MONTE CARLO METHOD; NAUSEA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; WEIGHT REDUCTION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MIGRAINE DISORDERS; PHARMACOECONOMICS; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH STATUS; HUMANS; MALE; MARKOV CHAINS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 77954979771     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11531180-000000000-00000     Document Type: Article

References (52)

1. Morey V, Rothrock JF. Examining the utility of in-clinic "rescue'' therapy for acute migraine. Headache 2008; 48 (6): 939-943
2. Lipton RB, Diamond S, Reed M, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41 (7): 646-657
3. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45 (8): 1012-1022
4. Adelman JU, Adelman LC, von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42 (10): 978-983
5. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 2001; 41 (4): 377-384
6. Rapoport AM. Pharmacological prevention of migraine. Clin Neurosci 1998; 5 (1): 55-59
7. Bland S. Migraine prophylaxis. J Pharm Soc Wis 2000 Nov/Dec; 20-24
8. Demaagd G. The pharmacological management of mi-graine: part 2. Preventive therapy [online]. PT 2008; 33 (8): 480-487 Available from URL: http://www.ptcommunity.com/ptjournal/fulltext/33/8/PTJ3308480.pdf [Accessed 2010 Feb 23]
9. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/ professionals/practice/pdfs/gl0090.pdf [Accessed 2010 Apr 26]
10. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22 (7): 491-512
11. Cole JC, Lin P, Rupnow MF. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 2007; 16 (7): 1231-1237
12. Rapoport A, Bigal M. Migraine preventive therapy: current and emerging treatment options. Neurol Sci 2005; 26: 111-120
13. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007; 47 Suppl. 1: S52-7
14. Soto J. Health economic evaluations using decision analytic modeling: principles and practices: utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 2002; 18 (1): 94-111
15. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005; 8 (6): 647-655
16. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus cafergot in the acute treatment of migraine. CNS Drugs 2005; 19 (7): 635-642
17. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20 (3): 183-194
18. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45 (8): 1012-1022
19. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (sero-tonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22 (8): 633-658
20. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358 (9294): 1668-1675
21. Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007; 21 (1): 73-82
22. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159 (8): 813-818
23. Brown JS, Neumann PJ, Papadopoulos G, et al. Migraine frequency and health utilities: findings from a multisite survey. Value Health 2008; 11 (2): 315-321
24. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291 (8): 965-973
25. Briggs A, Sculpher M. An introduction to Markov model-ling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-409
26. Maizels M, Houle T. Results of screening with the brief headache screen compared with a modified IDMigraine. Headache 2008; 48 (3): 385-394
27. Lipton RB, Bigal ME, Diamond M, et al. Migraine pre-valence, disease burden, and the need for preventive therapy. Neurology 2007; 68 (5): 343-349
28. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13 (6): 667-676
29. Gallagher RM, Kunkel R. Migraine medication attri-butes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43 (1): 36-43
30. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41 (7): 638-645 (Pubitemid 32777746)
31. Stewart WF, Lipton RB. Prevalence of migraine headache in the United States [abstract]. JAMA 1992; 267 (1): 64
32. Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006; 46 (10): 1552-1564
33. Linde K, Rossnagel K. Propranolol for migraine prophy-laxis. Cochrane Database Syst Rev 2004; (2): CD003225
34. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20 (9): 765-786
35. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160mg daily. Cephalalgia 2002; 22 (3): 209-221
36. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (7): 814-823
37. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in mi-graine prevention: results of a large controlled trial. Arch Neurol 2004; 61 (4): 490-495
38. Keskinbora K, Aydinli I. A double-blind randomized con-trolled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110 (10): 979-984
39. Peres MF, Silberstein S, Moreira F, et al. Patients' preference for migraine preventive therapy. Headache 2007; 47 (4): 540-545
40. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (1): 44-48
41. Bendtsen L, Jensen R, Olesen J. Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache. Electro-encephalogr Clin Neurophysiol 1996; 101 (5): 418-422
42. Keskinbora K, Aydinli I. A double-blind randomized con-trolled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110 (10): 979-984
43. Carroll JD, Reidy M, Savundra PA, et al. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 1990; 10 (2): 101-105
44. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251 (8): 943-950
45. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol versus propranolol versus placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69 (1): 1-8
46. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989; 9 (4): 247-253 (Pubitemid 20076151)
47. Stellar S, Ahrens SP, Meibohm AR, et al. Migraine pre-vention with timolol: a double-blind crossover study. JAMA 1984; 252 (18): 2576-2580
48. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58 (11): 1652-1659
49. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17 (2): 103-108
50. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multi-center, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31 (3): 542-559
51. Storey JR, Calder CS, Hart DE, et al. Topiramate in mi-graine prevention: a double-blind, placebo-controlled study. Headache 2001; 41 (10): 968-975
52. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol 2008; 59 (5): 237-242